Eric D. Shaff is CFO & VP at Seres Therapeutics, Inc. (MCRB). They have made 5 open-market trades across 1 company since 2016, most recently 2022-07-05.
CIK 0001609809
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MCRB | 96,334 | $201K |
Shares reported on the most recent Form 4, priced at the 2022-07-06 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MCRB | SELL | 2016-06-30 | 2016-06-30 | $29.54 | $134K | +9.9% | -66.2% | -54.2% |
| MCRB | SELL | 2016-06-27 | 2016-06-29 | $28.28 | $141K | +9.4% | -63.0% | -55.0% |
| MCRB | SELL | 2016-04-04 | 2016-04-06 | $28.85 | $189K | +1.6% | -18.9% | -2.0% |
| MCRB | SELL | 2016-03-31 | 2016-04-04 | $26.30 | $202K | +6.6% | -5.4% | +3.7% |
| MCRB | SELL | 2016-03-28 | 2016-03-29 | $24.07 | $132K | +21.5% | +15.7% | +6.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.